Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 19/20 | 0.58 |
| ▸ | CCNT1 | O60563 | 18/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.58 |
| ▸ | CDK1 | P06493 | 2/20 | 0.58 |
| ▸ | CDK4 | P11802 | 2/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.58 |
| ▸ | CCND1 | P24385 | 2/20 | 0.58 |
| ▸ | ABL2 | P42684 | 2/20 | 0.58 |
| ▸ | GSK3A | P49840 | 2/20 | 0.58 |
| ▸ | CDK7 | P50613 | 2/20 | 0.58 |
| ▸ | CCNH | P51946 | 2/20 | 0.58 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.58 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2026640 | 0.89 | CDK9 (0.74) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL2025346 | 0.88 | CCNT1 (0.63) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL2024692 | 0.87 | CDK9 (0.66) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL2024088 | 0.86 | CDK9 (0.64) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL2029828 | 0.86 | CDK9 (0.62) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL2048010 | 0.86 | CDK9 (0.62) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL2024632 | 0.86 | CYP1A2 (0.56) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL2028939 | 0.85 | CDK9 (0.59) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL2028758 | 0.85 | ABL1 (0.49) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL2026511 | 0.84 | CDK9 (0.54) | CDK9CCNT1MAP4K4CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516405-B1 | 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY | VIROSTATICS S R L (IT) | 2015-09-30 | — | — | EP | disclosed |
| US-9040529-B2 | 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2015-05-26 | — | — | US | disclosed |
| EP-2516405-A1 | 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY | Vichem Chemie Kutató KFT (HU) | 2012-10-31 | — | — | EP | disclosed |
| US-20120258968-A1 | 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY | VIROSTATICS S.R.L. (IT) | 2012-10-11 | — | — | US | disclosed |
| WO-2011077171-A1 | 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258968-A1 | 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY | CDK9, CDK19, CDKL3 | CDK9 1/4885CCNT1 47/4885MAP4K4 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.